Study of raxibacumab for anthrax infection
Part of Infections clinical trials.
This study observes people in the U.S. who have been treated with a specific anthrax drug (raxibacumab) from the national emergency supply. It helps doctors learn more about how the drug works in real-world cases of anthrax infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or the patient must have laboratory-confirmed systemic anthrax (a serious infection that can affect the lungs, gut, or skin with whole-body symptoms).
- You or the patient must have received the drug raxibacumab from the U.S. government's emergency supply (Strategic National Stockpile).
- You or the patient (or a legal guardian) must agree to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe and helpful raxibacumab is for people who are sick with inhalational anthrax after being exposed in a large incident. It includes all ages and also includes pregnant and breastfeeding people, focusing on outcomes from standard emergency clinical care.
This study looks at how well beta-lactam antibiotics (a common type of antibiotic) work in people being treated for infections at Imperial College NHS Trust. The information may help doctors make better dosing decisions.
This is an observational study (doctors follow people and record outcomes) for patients with systemic anthrax who received AIGIV from the CDC. It aims to learn how safe AIGIV is and what clinical outcomes patients experience after treatment.
This trial studies how safe and potentially helpful ANTHRASIL (AIGIV) is for people who have inhalational anthrax after exposure to a known source. If you have suspected or confirmed inhalational anthrax and were treated with AIGIV, you may be able to join this safety-and-benefit study.
This study tests a new combination of two antibiotics (meropenem and pralurbactam) given through an IV to treat serious abdominal infections. It is for adults who need hospital care and might be helped by a stronger infection-fighting drug.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Infections, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.